中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Scientific Advisory Board
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
Mar 20,2023
20
March 2023
AffaMed Technologies Announces TFDA Approval of MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready IOLs for Cataract Treatment in Taiwan
Mar 03,2023
03
March 2023
AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL
®
, the Progressive Extended Depth-of-Focus IOL
Jan 17,2023
17
January 2023
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Jul 22,2022
22
July 2022
AIER and AffaMed Therapeutics Reach Strategic Cooperation in Boao LeCheng
May 31,2022
31
May 2022
AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
<<
<
1
2
3
4
5
>
>>
下一页
